Cargando…

Real-World Effectiveness of Sodium Glucose Co-Transporter-2 Inhibitors in Japanese Patients with Diabetes Mellitus

INTRODUCTION: Sodium glucose co-transporter-2 inhibitors (SGLT2i) have been on the market for 5 years in Japan. We explored the real-world effectiveness of SGLT2i in Japan. METHODS: We retrospectively analyzed two large Japanese administrative databases from JMDC Inc.: insurance-dataset (I-dataset)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ito, Yuichiro, Van Schyndle, James, Nishimura, Takuya, Sugitani, Toshifumi, Kimura, Tomomi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848551/ https://www.ncbi.nlm.nih.gov/pubmed/31617152 http://dx.doi.org/10.1007/s13300-019-00708-w

Ejemplares similares

Characteristics of Patients with Diabetes Initiating Sodium Glucose Co-transporter-2 Inhibitors (SGLT2i): Real-World Results from Three Administrative Databases in Japan
por: Ito, Yuichiro, et al.
Publicado: (2019)

Drug Utilization Patterns in Patients with Diabetes Initiating Sodium Glucose Co-Transporter-2 Inhibitors (SGLT2i) in Japan: A Multi-Database Study (2014–2017)
por: Ito, Yuichiro, et al.
Publicado: (2019)

Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use
por: McGovern, Andrew, et al.
Publicado: (2017)

Feasibility and Safety of Sodium Glucose Cotransporter-2 Inhibitors in Adults with Heart Failure after the Fontan Procedure
por: Muneuchi, Jun, et al.
Publicado: (2022)

Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Type 1 Diabetes Mellitus on Body Composition and Glucose Variabilities: Single-Arm, Exploratory Trial
por: Baba, Yusuke, et al.
Publicado: (2021)

Comparison of Efficacy of Dipeptidyl Peptidase‐4 Inhibitors and Sodium‐Glucose Co‐Transporter 2 Inhibitors Between Japanese and Non‐Japanese Patients: A Meta‐Analysis
por: Ito, Yuka, et al.
Publicado: (2020)

Reduction in cardiovascular disease events in patients with type 2 diabetes mellitus treated with a sodium–glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase‐4 inhibitor: A real‐world retrospective administrative database analysis in Japan
por: Kashiwagi, Atsunori, et al.
Publicado: (2022)

Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)
por: McGovern, Andrew, et al.
Publicado: (2017)

A novel strategy for the treatment of diabetes mellitus - sodium glucose co-transport inhibitors
por: Niazi, Asfandyar Khan, et al.
Publicado: (2010)

Real-world evaluation of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors for managing type 2 diabetes mellitus: a retrospective multi-ethnic cohort study
por: Goh, Louise Gek Huang, et al.
Publicado: (2022)

Observational research on sodium glucose co‐transporter‐2 inhibitors: A real breakthrough?
por: Raschi, Emanuel, et al.
Publicado: (2018)

Euglycemic diabetic ketoacidosis by sodium glucose co-transporter inhibitors: Real but preventable concern
por: Raut, Monish S, et al.
Publicado: (2017)

Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Korean Patients with Type 2 Diabetes Mellitus in Real-World Clinical Practice
por: Hong, A Ram, et al.
Publicado: (2019)

Cardiovascular and mortality benefits of sodium–glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia
por: Real, Jordi, et al.
Publicado: (2021)

Effects of luseogliflozin, a sodium–glucose co‐transporter 2 inhibitor, on 24‐h glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus: a randomized, double‐blind, placebo‐controlled, crossover study
por: Nishimura, R., et al.
Publicado: (2015)

Sodium-Glucose Co-Transporter 2 Inhibitors Reduce Macular Edema in Patients with Diabetes mellitus
por: Tatsumi, Tomoaki, et al.
Publicado: (2022)

The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors – Real-World Data
por: Gallwitz, Baptist
Publicado: (2018)

Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier’s gangrene
por: Yang, Jeff Yufeng, et al.
Publicado: (2020)

Challenges and opportunities in real‐world evidence on the renal effects of sodium‐glucose cotransporter‐2 inhibitors
por: Fadini, Gian Paolo, et al.
Publicado: (2021)

Cardiovascular Effects of Sodium Glucose Co-transporter-2 Inhibitors in Patients with Type 2 Diabetes Mellitus
por: Kumar, Surender, et al.
Publicado: (2019)

Role of sodium-glucose co-transporter-2 inhibitors in the management of heart failure in patients with diabetes mellitus
por: Alkagiet, Stelina, et al.
Publicado: (2020)

Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?
por: Shao, Shih-Chieh, et al.
Publicado: (2019)

Amelioration of pancreatic fat accumulation in Japanese type 2 diabetes patients treated with sodium‐glucose cotransporter 2 inhibitors: a retrospective study
por: Horii, Tomomi, et al.
Publicado: (2021)

Assessing Patient Satisfaction Following Sodium Glucose Co-Transporter 2 Inhibitor Treatment for Type 1 Diabetes Mellitus: A Prospective Study in Japan
por: Ishibashi, Ryoichi, et al.
Publicado: (2020)

Adverse Effect Profile and Effectiveness of Sodium Glucose Co-transporter 2 Inhibitors (SGLT2i) - A Prospective Real-world Setting Study
por: Gill, Harmandeep Kaur, et al.
Publicado: (2019)

The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study
por: Goldman, Adam, et al.
Publicado: (2023)

Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data
por: Arai, Taeang, et al.
Publicado: (2021)

The potential role of sodium glucose co‐transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus
por: Brunton, S. A.
Publicado: (2015)

Sodium‐glucose co‐transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician
por: Dandona, Paresh, et al.
Publicado: (2017)

Eligibility of sodium–glucose co‐transporter‐2 inhibitors among patients with diabetes mellitus admitted for heart failure
por: Sharma, Abhinav, et al.
Publicado: (2019)

Sodium-glucose Co-transporters-2 Inhibitors and Heart Failure: State of the Art Review and Future Potentials
por: Kato, Eri Toda, et al.
Publicado: (2020)

Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study
por: Kim, Young-Gun, et al.
Publicado: (2018)

Medication counselling with sodium glucose transporter 2 inhibitor therapy
por: Kalra, Sanjay, et al.
Publicado: (2014)

Harms and benefits of sodium-glucose co-transporter 2 inhibitors
por: Chesterman, Thomas, et al.
Publicado: (2020)

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
por: Erythropoulou-Kaltsidou, Anastasia, et al.
Publicado: (2019)

Sodium-glucose co-transporter 2 inhibitors beyond diabetes
por: Williams, Dimity L, et al.
Publicado: (2022)

Sodium glucose co-transport 2 inhibitors for gout treatment
por: Somagutta, Manoj Kumar Reddy, et al.
Publicado: (2022)

Associations of Plasma Concentration Profiles of Dapagliflozin, a Selective Inhibitor of Sodium–Glucose Co-Transporter Type 2, with Its Effects in Japanese Patients with Type 2 Diabetes Mellitus
por: Hayakawa, Tetsuo, et al.
Publicado: (2022)

Clinical application of sodium-glucose cotransporter 2 inhibitor into a real-world setting of heart failure care
por: Tanaka, Atsushi, et al.
Publicado: (2020)

Sodium-glucose cotransporter 2 inhibitors: a practical guide for the Dutch cardiologist based on real-world experience
por: Zwart, K., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r7bd25c1luvbd2uaqj7nr4nck6